Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0543 • ACR Convergence 2025
Unveiling Sacroiliac Joint Involvement in Psoriatic Arthritis: MRI, Radiographic, and Clinical Insights from 581 European Routine Care Patients
Nora Vladimirova¹, Anna EF Hadsbjerg², Simon Krabbe³, Adrian Ciurea⁴, Kristýna Bubová⁵, Monika Gregova⁵, Michael Nissen⁶, Burkhard Moeller⁷, Raphael Micheroli⁴, Susanne Pedersen⁸, Jakub Zavada⁵, Ziga Snoj⁹, Karlo Pintaric⁹, Bjorn Gudbjornsson¹⁰, Ziga Rotar¹¹, iris Eshed¹², Iwona Iwona Sudol-Szopinska¹³, Kasper Gosvig¹⁴, Torsten Diekhoff¹⁵, Robert G. W. Lambert¹⁶, Manouk de Hooge¹⁷, Maurice Donzallaz¹⁸, Alexander Bernatschek¹⁸, Merete Hetland¹⁹, Lykke Ørnbjerg²⁰ and Mikkel Ostergaard²¹, ¹Rigshospitalet-Glostrup, Copenhagen, Denmark, ²Copenhagen Center for Arthritis Research, COPECARE, Glostrup, Denmark, ³Rigshospitalet, København, Denmark, ⁴University Hospital Zurich, Zurich, Switzerland, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic, ⁶Rheumatology Department, Geneva University Hospital, Geneva, Switzerland, ⁷Department of Rheumatology and Immunology, Inselspital, University Hospital Bern,, Bern, Swaziland, ⁸Rigshospitalet, København �, Denmark, ⁹Institute of Radiology, UMC Ljubljana,, Ljubliana, Slovenia, ¹⁰Landspitali University Hospital; Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹¹University Medical Centre Ljubljana, Ziri, Slovenia, ¹²Department of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer affiliated with School of Medicine, Tel Aviv University, Tel Aviv, Israel, ¹³Department of Radiology, National Institute of Geriatrics, Rheumatology and Rehabilitation,, Warsaw, Poland, ¹⁴Department of Radiology, Copenhagen University Hospital Herlev-Gentofte,, Copenhagen, Denmark, ¹⁵Charite Universitetsmedizin Berlin, Berlin, Germany, ¹⁶University of Alberta, Department of Radiology & Diagnostic Imaging, Edmonton, AB, Canada, ¹⁷Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ¹⁸Department of Rheumatology, University Hospital of Zurich, University of Zurich,, Zurich, Switzerland, ¹⁹Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, ²⁰Rigshospitalet, Glostrup, Denmark, ²¹Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark
Background/Purpose: Axial involvement in psoriatic arthritis (axPsA) is associated with more severe disease and greater pain compared to PsA with only peripheral disease. However, a…
Abstract Number: 0362 • ACR Convergence 2025
Drug Persistence of IL-17A Inhibitors Among Patients with PsA: Real-World Data from the CorEvitas PsA/SpA Registry
Philip J. Mease¹, Nicole Middaugh², Maya Marchese³, Skyler Peterson³, Burcu Ertugrul Vardar⁴, Russel Burge⁵, Natalia Bello⁶, Marcus Ngantcha⁷, Joseph F Merola⁸, Louis Bessette⁹ and Alexis Ogdie¹⁰, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³CorEvitas, LLC, Waltham, ⁴Eli Lilly Cork GBS Ltd, Dublin, Dublin, Ireland, ⁵Eli Lilly and Company, Indianapolis, ⁶Eli Lilly, Indianapolis, IN, ⁷Eli Lilly GBS Cork Ltd, Cork, Ireland, ⁸Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁹Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ¹⁰University of Pennsylvania, Philadelphia, PA
Background/Purpose: IL-17A inhibitors (IL-17Ai) are considered recommended biologic therapies for PsA per current treatment guidelines1,2. Real-world evidence (RWE) studies on IL-17Ai drug persistence among patients…
Abstract Number: 2391 • ACR Convergence 2025
Antinuclear Antibody Positivity in Patients with Psoriasis and Psoriatic Arthritis and the Risk of Developing Clinical Symptoms of SLE Following TNF Inhibitor Therapy
Damira Sereda¹, Leilani Leechalad¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY
Background/Purpose: It has been reported that the presence of positive ANA in patients treated with TNF inhibitors (TNFi) could be associated with the development of…
Abstract Number: 2356 • ACR Convergence 2025
Clinical Efficacy in Male and Female Patients With Active Psoriatic Arthritis Treated With Deucravacitinib: A Pooled Analysis of Pivotal Phase 3 Studies
Lihi Eder¹, Philip J. Mease², Joseph F Merola³, Alexis Ogdie⁴, Atul Deodhar⁵, Laura Coates⁶, Stefan Varga⁷, Navya Kalapala⁷, Ying-Ming Jou⁸, Eleni Vritzali⁹ and Laure Gossec¹⁰, ¹University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ⁵Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Bristol Myers Squibb, Princeton, ⁹Bristol Myers Squibb, Boudry, Switzerland, ¹⁰Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: PsA affects male and female patients equally; however, variations in clinical manifestations and treatment responses between sexes have been reported. Deucravacitinib is an oral,…
Abstract Number: 2314 • ACR Convergence 2025
Radiographic and Ultrasonographic Assessments of Sesamoid Index in Patients with Psoriatic Arthritis
Hung Vo¹, Eugene Kissin² and Pablo Weilg³, ¹Boston Medical Center, Peabody, MA, ²Boston University, Newton, MA, ³Kymera Independent Physicians, Roswell, NM
Background/Purpose: The sesamoid index (SI), a radiographic measure of medial thumb sesamoid area, was originally described as a diagnostic tool in acromegaly¹ and later proposed…
Abstract Number: 1879 • ACR Convergence 2025
Infections in Hospitalized Patients With and Without Psoriatic Arthritis (2016–2021): A National Inpatient Sample Study
Ayema Haque, Ana Salas, Bruna Diniz, Harshank Patel and Philip Kroth, Western Michigan University School of Medicine, Kalamazoo, MI
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disorder affecting up to 30% of psoriasis patients and is associated with increased infection risk. This…
Abstract Number: 1456 • ACR Convergence 2025
Long-Term Safety of Tildrakizumab Through Week 208 in Patients With Psoriatic Arthritis: Results From the Phase 2b Open-Label Extension Study
Philip J. Mease¹, Saima Chohan², Ferran José Garcia Fructuoso³, Michael E Luggen⁴, Proton Rahman⁵, Siba Raychaudhuri⁶, Alice B. Gottlieb⁷, Richard Chou⁸, Marek Honczarenko⁸, Benjamin P Soule⁸, Shantanu Mehta⁸, Tushar Nishandar⁹, Arvind Tripathi⁸ and Mudgal Kothekar¹⁰, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Arizona Arthritis and Rheumatology Research, PLLC,, Pheonix, AZ, ³Servicio de Reumatología, Hospital CIMA Sanitas, Paseo Manuel Girona, Barcelona, Spain, ⁴Division of Rheumatology, Allergy, and Immunology, University of Cincinnati College of Medicine, Cincinnati, OH, ⁵Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ⁶UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ⁷Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, ⁸Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁹Sun Pharmaceutical Industries Limited, Andheri (E), Mumbai, India, ¹⁰Sun Pharma Advanced Research Company Limited, Andheri (E), Princeton, NJ
Background/Purpose: Tildrakizumab (TIL) is an anti–IL-23 p19 monoclonal antibody approved for the treatment of adults with moderate-to-severe plaque psoriasis. In a Phase 2b trial in…
Abstract Number: 1416 • ACR Convergence 2025
Structural Damage Progression in the Spine in Patients with Psoriatic Arthritis: Findings from a Longitudinal Cohort Study
Fadi Kharouf¹, Pankti Mehta², Virginia Carrizo Abarza³, Shangyi Gao⁴, Daniel Pereira⁵, Dafna D. Gladman⁶, Vinod Chandran⁷ and Denis Poddubnyy⁸, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ³Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ⁴Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ⁵University Health Network, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: Axial involvement is one of the key features of psoriatic arthritis (PsA) and is associated with increased disease burden. However, rates and predictors of…
Abstract Number: 1007 • ACR Convergence 2025
Accelerometry-Derived Activity and Sleep Patterns in the NIH All of Us Cohort: Insights and Predictive Potential for Inflammatory Arthritis
adeep Kulkarni¹, Jose Scher², Rebecca Haberman³ and Souptik Barua¹, ¹New York University Grossman School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Langone Health, New York, NY
Background/Purpose: Patients with inflammatory arthritis (IA) report reduced physical activity and poor sleep, However, much remains unknown about the extent and impact of this relationship.…
Abstract Number: 0564 • ACR Convergence 2025
Improvements in Patient Reported Outcomes Through 24 Weeks of Guselkumab Treatment in Participants with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
Alice Gottlieb¹, Joseph F Merola², Philip J. Mease³, Christopher Ritchlin⁴, Jose U. Scher⁵, Kimberly Parnell Lafferty⁶, Daphne Chan⁷, Soumya Chakravarty⁸, Wayne Langholff⁹, Yanli Wang⁹, Olivia Choi, MD, PhD, FAAD⁷, Yevgeniy Krol¹⁰ and Alexis Ogdie¹¹, ¹Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, ²Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ³Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Rochester Medical Center, Canandaigua, NY, ⁵New York University School of Medicine, New York, NY, ⁶Johnson & Johnson, Dermatology, Horsham, PA, ⁷Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ⁸Johnson & Johnson, Horsham, PA, USA; Drexel University College of Medicine, Philadelphia, PA, USA, Villanova, PA, ⁹Johnson & Johnson, Biostatistics, Spring House, PA, ¹⁰Johnson & Johnson, Horsham, PA, ¹¹University of Pennsylvania School of Medicine, Philadelphia, PA
Background/Purpose: Guselkumab (GUS), a fully human IL-23p19-subunit inhibitor, has demonstrated efficacy in significantly improving psoriatic arthritis (PsA) signs and symptoms in participants (pts) with active…
Abstract Number: 0542 • ACR Convergence 2025
Transition from Psoriasis to Psoriatic Arthritis: Does Family History Influence the Time to Onset of Arthritis in Psoriasis Patients?
Marta Flores¹, Juan de Luque², Mitndbaim Parra³, Alejandro Escudero Contreras⁴, María Dolores López-Montilla⁵ and Clementina López Medina⁶, ¹¹. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Spain, Spain, ²Reina Sofia University Hospital, CÓRDOBA, Andalucia, Spain, ³¹. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Cordoba, Spain, ⁴IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁵Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, ⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a debilitating disease that occurs in up to one-third of patients with psoriasis (Pso), generally manifesting after the onset of…
Abstract Number: 0343 • ACR Convergence 2025
Impact of Janus Kinase Inhibitors on Bone Mineral Density and Microarchitecture in Rheumatoid and Psoriatic Arthritis: Insights from a Real-World Cohort
Edgar Wiebe¹, Dörte Huscher², Zhivana Boyadzhieva³, Andriko Palmowski⁴, Sandra Hermann¹, Burkhard Muche⁴, Arnd Kleyer⁵, David Simon⁶, Gerhard Krönke⁷, Paula Hoff⁸ and FRANK BUTTGEREIT⁹, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁷Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁸Endokrinologikum Berlin, Medizinisches Versorgungszentrum (MVZ) am Gendarmenmarkt, Berlin, Berlin, Germany, ⁹Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Janus kinase (JAK) inhibitors are an important treatment option for rheumatoid arthritis (RA) and psoriatic arthritis (PsA). By disrupting pro-inflammatory cytokine signaling (e.g., IL-6,…
Abstract Number: 2375 • ACR Convergence 2025
Ixekizumab Provided Rapid Improvements in Quality of Life and Disease Activity in Patients with Psoriatic Arthritis: Findings from a Real-World Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
KURT OELKE¹, Emily Edson-Heredia², Sarah Ross³, Jennifer Marie Pustizzi⁴, Ali Sheikhi Mehrabadi⁴, Natalia Bello⁴, Frederick Murphy⁵, Shikha Singla⁶, Siba Raychaudhuri⁷, Philip J Mease⁸ and Arthur Kavanaugh⁹, ¹rheumatic disease center, Glendale, WI, ²eli lilly, indianapolis, ³Lilly, Indianapolis, IN, ⁴Eli Lilly, Indianapolis, IN, ⁵Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁶Medical College of Wisconsin, Milwaukee, WI, ⁷UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ⁸University of Washington, Seattle, WA, ⁹University of California, San Diego, School of Medicine, San Diego, CA

Background/Purpose: Ixekizumab (IXE) is a selective interleukin-17A antagonist that has proven effective in Phase 3 and 4 clinical trials for patients with psoriatic arthritis (PsA).Methods:…
Abstract Number: 2355 • ACR Convergence 2025
Ixekizumab Provided Rapid Improvement in Key Patient Subgroups with Psoriatic Arthritis: Findings from a Prospective Observational Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
KURT OELKE¹, Sarah Ross², Emily Edson-Heredia³, Jennifer Pustizzi⁴, Ali Sheikhi Mehrabadi⁵, Natalia Bello⁵, Frederick Murphy⁶, Shikha Singla⁷, Siba Raychaudhuri⁸, Philip J Mease⁹ and Arthur Kavanaugh¹⁰, ¹rheumatic disease center, Glendale, WI, ²Lilly, Indianapolis, IN, ³eli lilly, indianapolis, ⁴Eli Lilly, Hammonton, NJ, ⁵Eli Lilly, Indianapolis, IN, ⁶Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁷Medical College of Wisconsin, Milwaukee, WI, ⁸UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ⁹University of Washington, Seattle, WA, ¹⁰University of California, San Diego, School of Medicine, San Diego, CA

Background/Purpose: Ixekizumab (IXE) is an FDA-approved monoclonal antibody that targets interleukin-17A.Methods: Psoriatic Arthritis Real-World Study in the US (PARTUS) was a prospective, multicenter, non-interventional cohort…
Abstract Number: 2313 • ACR Convergence 2025
From Plaque to Plaque: Bridging Oral and Systemic Inflammation in Psoriasis and PsA
guru Vijay Chagalakondu, Vijaya prasanna Parimi and Pradeep S Anand, ESIC Medical College and Super Specilaity Hospital, hyderabad, Telangana, India
Background/Purpose: Psoriasis and psoriatic arthritis (PsA) are two chronic inflammatory conditions which have similar immunopathological mechanisms which also cause periodontal disease. The association between these…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].